Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2017

01-07-2017 | Original Article

Association of CCND1 Gene c.870G>A Polymorphism with Breast Cancer Risk: A Case-ControlStudy and a Meta-Analysis

Authors: Zahra Soleimani, Davood Kheirkhah, Mohammad Reza Sharif, Alireza Sharif, Mohammad Karimian, Younes Aftabi

Published in: Pathology & Oncology Research | Issue 3/2017

Login to get access

Abstract

Cyclin D1 (CCND1) plays an essential role in regulating the progress of the cell cycle from G1 to S phase. There is a common c.870G>A polymorphism in the CCND1 gene. The aim of this study was to investigate the association of CCND1 gene c.870G>A polymorphism with breast cancer risk in a case-control study, which followed by a meta-analysis and an in silico analysis. Three hundred and thirty-five subjects composed of 174 women with breast cancer and 161 healthy controls were included in the case-control study. CCND1 gene c.870G>A genotyping was performed by PCR-RFLP. Meta-analysis was done for 14 studies composed of 7281 cases and 6820 controls. Some bioinformatics tools were applied to investigate the effects of c.870G>A on the mRNA splicing and structure. Our data obtained from case-control study revealed that GA genotype (OR: 1.89, 95%CI: 1.12–3.17, p = 0.017), AA genotype (OR: 1.95, 95%CI: 1.08–3.53, p = 0.027), and A allele (OR: 1.44, 95%CI: 1.06–1.95, p = 0.019) were significantly associated with breast cancer risk. The results of meta-analysis showed a significant association between CCND1 c.870G>A polymorphism and breast cancer risk, especially in Caucasian population. In silico analysis revealed that c.870G>A transition affect CCND1 mRNA splicing and secondary structure.
Literature
1.
2.
Fabris VT (2014) From chromosomal abnormalities to the identification of target genes in mouse models of breast cancer. Cancer Genet 207:233–246CrossRefPubMed
3.
4.
Strumylaitė L, Mechonošina K, Tamašauskas S (2010) Environmental factors and breast cancer. Medicina (Kaunas) 46:867–873
5.
Theodoropoulos GE, Michalopoulos NV, Pantou MP, Kontogianni P, Gazouli M, Karantanos T, Lymperi M, Zografos G (2012) Caspase 9 promoter polymorphisms confer increased susceptibility to breast cancer. Cancer Genet 205:508–512CrossRefPubMed
6.
Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11:558–572CrossRefPubMed
7.
Knudsen KE, Diehl JA, Haiman CA, Knudsen ES (2006) Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25:1620–1628CrossRefPubMed
8.
Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J, Diehl JA, Knudsen KE (2005) A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene 24:431–444CrossRefPubMed
9.
10.
Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J (1995) Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11:1005–1011PubMed
11.
Wu Y, Fu H, Zhang H, Huang H, Chen M, Zhang L, Yang H, Qin D (2014) Cyclin D1 (CCND1) G870A polymorphisms and cervical cancer susceptibility: a meta-analysis based on ten case–control studies. Tumour Biol 35:6913–6918CrossRefPubMed
12.
Grieu F, Malaney S, Ward R, Joseph D, Iacopetta B (2003) Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res 23:4257–4259PubMed
13.
Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Weitzer W, Leithner A, Samonigg H (2003) The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat 82:165–168CrossRefPubMed
14.
Försti A, Angelini S, Festa F, Sanyal S, Zhang Z, Grzybowska E, Pamula J, Pekala W, Zientek H, Hemminki K, Kumar R (2004) Single nucleotide polymorphisms in breast cancer. Oncol Rep 11:917–922PubMed
15.
Ceschi M, Sun CL, Van Den Berg D, Koh WP, MC Y, Probst-Hensch N (2005) The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 26:1457–1464CrossRefPubMed
16.
Shu XO, Moore DB, Cai Q, Cheng J, Wen W, Pierce L, Cai H, Gao Y, Zheng W (2005) Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomark Prev 14:91–97
17.
Onay UV, Aaltonen K, Briollais L, Knight JA, Pabalan N, Kilpivaara O, Andrulis I, Blomqvist C, Nevanlinna H, Ozcelik H (2008) Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 8:6CrossRefPubMedPubMedCentral
18.
Yu CP, Yu JC, Sun CA, Tzao C, Ho JY, Yen AM (2008) Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat 107:95–102CrossRefPubMed
19.
Naidu R, Yip CH, Taib NA (2008) Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma 55:87–95PubMed
20.
Justenhoven C, Pierl CB, Haas S, Fischer HP, Hamann U, Baisch C, Harth V, Spickenheuer A, Rabstein S, Vollmert C, Illig T (2009) Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. Int J Cancer 124:2077–2081CrossRefPubMed
21.
Yaylim-Eraltan I, Ergen A, Görmüs U, Arikan S, Küçücük S, Sahin O, YİĞİT N, Yildiz Y, Isbir T (2009) Breast cancer and cyclin D1 gene polymorphism in Turkish women. In Vivo 23:767–772PubMed
22.
Jeon S, Choi JY, Lee KM, Park SK, Yoo KY, Noh DY, Ahn SH, Kang D (2010) Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer. Breast Cancer Res Treat 121:737–742CrossRefPubMed
23.
Canbay E, Eraltan IY, Cercel A, Isbir T, Gazioglu E, Aydogan F, Cacina C, Cengiz A, Ferahman M, Zengin E, Unal H (2010) CCND1 and CDKN1B polymorphisms and risk of breast cancer. Anticancer Res 30:3093–3098PubMed
24.
Wasson MK, Chauhan PS, Singh LC, Katara D, Dev Sharma J, Zomawia E, Kataki A, Kapur S, Saxena S (2014) Association of DNA repair and cell cycle gene variations with breast cancer risk in northeast Indian population: a multiple interaction analysis. Tumour Biol 35:5885–5894CrossRefPubMed
25.
26.
Mantel N, Haenszel W (1959) Statistical aspects of the analysisof data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed
27.
28.
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed
29.
30.
Wang M, Marín A (2006) Characterization and prediction of alternative splice sites. Gene 366:219–227CrossRefPubMed
31.
Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouzé P, Brunak S (1996) Splice site prediction in Arabidopsis thaliana DNA by combining local and global sequence information. Nucleic Acids Res 24:3439–3452CrossRefPubMedPubMedCentral
32.
Sabarinathan R, Tafer H, Seemann SE, Hofacker IL, Stadler PF, Gorodkin J (2013) The RNAsnp web server: predicting SNP effects on local RNA secondary structure. Nucleic Acids Res 41:W475–W479CrossRefPubMedPubMedCentral
33.
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M (2015) STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43:447–452CrossRef
34.
Ormandy CJ, Musgrove EA, Hui R, Daly RJ (2003) Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78:323–335CrossRefPubMed
35.
Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812–1817PubMed
36.
Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7:812–821CrossRefPubMed
37.
Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL (1998) C-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 18:4499–4508CrossRefPubMedPubMedCentral
38.
Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, DeFazio A, Watts CK, Musgrove EA, Sutherland RL (1993) Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127–2133PubMed
39.
Lu C, Dong J, Ma H, Jin G, Hu Z, Peng Y, Guo X, Wang X, Shen H (2008) CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 116:571–575CrossRefPubMed
40.
Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H, Hara M, Saito I (1998) Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 16:1701–1702CrossRefPubMed
41.
Weinstein IB, Begemann M, Zhou P, Han EK, Sgambato A, Doki Y, Arber N, Ciaparrone M, Yamamoto H (1997) Disorders in cell circuitry associated with multistage cacinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 3:2696–2702PubMed
42.
Zhang J, Li Y, Wang R, Wen D, Sarbia M, Kuang G, Wu M, Wei L, He M, Zhang L, Wang S (2003) Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer 105:281–284CrossRefPubMed
43.
Howe D, Lynas C (2001) The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica 86:563–569PubMed
44.
Jamali S, Karimian M, Nikzad H, Aftabi Y (2016) The c. − 190 C>A transversion in promoter region of protamine1 gene as a genetic risk factor for idiopathic oligozoospermia. Mol Biol Rep 43:795–802
45.
Nikzad H, Karimian M, Sareban K, Khoshsokhan M, Hosseinzadeh Colagar A (2015) MTHFR-Ala222Val and male infertility: a study in Iranian men, an updated meta-analysis and an in silico-analysis. Reprod BioMed Online 31:668–680CrossRefPubMed
46.
Karimian M, Nikzad H, Tameh AA, Taherian A, Darvishi FZ, Haghighatnia MJ (2015) SPO11-C631T gene polymorphism: association with male infertility and an in silico-analysis. J Family Reprod Health 9:155–163PubMedPubMedCentral
47.
Karimian M, Hosseinzadeh Colagar A (2016) Methionine synthase A2756G transition might be a risk factor for male infertility: evidences from seven case-control studies. Mol Cell Endocrinol 425:1–10CrossRefPubMed
48.
Aftabi Y, Colagar AH, Mehrnejad F (2016) An in silico approach to investigate the source of the controversial interpretations about the phenotypic results of the human AhR-gene G1661A polymorphism. J Theor Biol 21(393):1–5CrossRef
49.
Shen LX, Basilion JP, Stanton VP Jr (1999) Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci U S A 96:7871–7876CrossRefPubMedPubMedCentral
50.
Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, Ghandour G, Perkins N, Winchester E, Spencer J, Kruglyak L (1998) Large-scale identification, mapping, and genotyping of single nucleotide polymorphisms in the human genome. Science 280:1077–1082CrossRefPubMed
51.
Pabalan N, Bapat B, Sung L, Jarjanazi H, Francisco-Pabalan O, Ozcelik H (2008) Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomark Prev 17:2773–2781CrossRef
52.
Lu C, Dong J, Ma H, Jin G, Hu Z, Peng Y, Guo X, Wang X, Shen H (2009) CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 116:571–575CrossRefPubMed
53.
Cui J, Shen L, Wang Y (2012) Specific CCND1 G870A alleles associated with breast cancer susceptibility: a meta-analysis of 5,528 cases and 5,353 controls. Asian Pac J Cancer Prev 13:5023–5025CrossRefPubMed
54.
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, Shi B (2015) Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res 5(10):2929PubMedPubMedCentral
55.
Perou CM (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16(Supplement 1):61–70CrossRefPubMed
56.
57.
Arnold A, Papanikolaou A (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23(18):4215–4224CrossRefPubMed
58.
Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, Meyyappan M, Rosfjord EC, Rabindran SK (2006) Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat 95(2):185–194CrossRefPubMed
59.
Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6(1):1CrossRef
60.
Zang Y, Zhao S, Doll MA, Hein DW (2004) The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenet Genomics 14(11):717–723CrossRef
Metadata
Title
Association of CCND1 Gene c.870G>A Polymorphism with Breast Cancer Risk: A Case-ControlStudy and a Meta-Analysis
Authors
Zahra Soleimani
Davood Kheirkhah
Mohammad Reza Sharif
Alireza Sharif
Mohammad Karimian
Younes Aftabi
Publication date
01-07-2017
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0165-3

Other articles of this Issue 3/2017

Pathology & Oncology Research 3/2017 Go to the issue

Original Article

The hOGG1 Ser326Cys Gene Polymorphism and Breast Cancer Risk in Saudi Population

Original Article

Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study

Original Article

Rare Case of an Ancient Craniofacial Osteosarcoma with Probable Surgical Intervention

Original Article

More Cases of Benign Testicular Teratomas are Detected in Adults than in Children. A Clinicopathological Study of 543 Testicular Germ Cell Tumor Cases

Original Article

Comprehensive DNA Methylation and Mutation Analyses Reveal a Methylation Signature in Colorectal Sessile Serrated Adenomas

Original Article

Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits